ESR1 and hepatocellular carcinoma: Wei et al. reported that in patients with hepatitis-B-virus-associated hepatocellular carcinoma, estrogen binds to intracellular estrogen receptors in Kupffer cells, which inhibits the STAT3 and NFκB pathways, which are required in order to activate the IL-6 promoter [23].